INR101

Phase 3Small molecule

YYunhe Pharmaceutical (Tianjin) Co., Ltd

INR101 is one of 29 small molecule programs targeting Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerNot yet recruiting

Prostate CancerPhase 3

Not yet recruiting

Competition

Competitive Landscape

314 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

GM-CSF

YY-mAbs Therapeutics

Phase 3

8 2

Perflutren Lipid Microspheres

SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Phase 3

1 3

Androgen Deprivation Treatment

MMedical University of Vienna

Phase 3

1 4

INR101

YYunhe Pharmaceutical (Tianjin) Co., Ltd

Phase 3

3 5

Antibiotic Prophylaxis

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 6

Trexall

Jazz Pharmaceuticals

Preclinical

—7

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 8

Duragesic

CCephalon

Preclinical

1 9

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 10

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Not yet recruiting

Prostate Cancer

NCT06922929

Clinical

Trials by Indication[1]

Prostate Cancer3 trials

Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.

Not yet recruiting·YYunhe Pharmaceutical (Tianjin) Co., Ltd·Phase 3·NCT06922903·240 enrolled

A Study of PET/CT Imaging Using INR101 Injection in Healthy Male Subjects and Patients With Suspected Prostate Cancer

Completed·YYunhe Pharmaceutical (Tianjin) Co., Ltd·Phase 1/2·NCT06472531·32 enrolled

A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment

Not yet recruiting·YYunhe Pharmaceutical (Tianjin) Co., Ltd·Phase 3·NCT06922929·110 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for INR101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — INR101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for INR101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yunhe Pharmaceutical (Tianjin) Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: YYunhe Pharmaceutical (Tianjin) Co., Ltd

INR101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Prostate Cancer3 trials

References

Drug Info

Quick Facts

Related News